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ABSTRACT 
PRODUCTION OF A MONOCLONAL ANTIBODY AGAINST THE ALPHA 4 BETA 
7 INTEGRIN 
by Asima Khan 
This study describes an attempt to produce a monoclonal antibody (mAb) against 
the human alpha 4 beta 7 (a4(37) gut-homing integrin found on lymphocytes. The 
recruitment of lymphocytes via the a4[37 receptor to the gut has been associated with 
inflammatory bowel disease (IBD). A novel immunization strategy was employed in 
generating polyclonal antibodies (pAb) in C57BL/6 mice. (37 knock-out (K/O) mice were 
immunized with (37 wild-type (WT) mouse splenocytes with cell-surface (37. As a final 
boost, mice were injected with human peripheral blood mononuclear cells (PBMC), with a 
rationale of boosting epitopes shared between murine and human (37. Immune sera and 
clones generated by hybridoma technology were screened using the enzyme-linked 
immunosorbent assay (ELISA) and flow cytometry. Despite binding to both mouse cells 
and PBMCs expressing a4(37, the mAb produced is unlikely to be anti-a4(37 because it 
generated a different staining pattern than the positive control, ACT-1, on T cell subsets 
that migrate to the gut. 
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PREFACE 
The following thesis consists of three chapters and the appendices. The first 
chapter is a detailed introduction of inflammatory bowel disease, the mechanism of 
lymphocyte homing, the role of the alpha 4 beta 7 integrin, strategies for treating the 
disease and our research goals. The second chapter is presented in manuscript format in 
accordance with guidelines from the Journal of Immunology. Chapter II has its own 
separate list of references cited. Chapter III is a detailed discussion of the results and 
future direction for the study. Chapter III is followed by a list of references cited for both 
Chapters I and III. The appendices provide supplementary materials associated with the 
research. 
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CHAPTER I 
INTRODUCTION 
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INTRODUCTION 
Inflammatory Bowel Disease 
IBD is comprised of Crohn's disease (CD) and ulcerative colitis (UC), two chronic 
intestinal inflammatory conditions. UC involves inflammation of the inner lining of the 
large intestine or colon while CD extends deeper into the intestinal wall and commonly 
affects both the large and small intestine and other organs in the digestive tract (1). 
Patients typically experience lifelong recurring symptoms such as bloody diarrhea and 
abdominal cramping during bowel movements. There are an average of 6 new cases of 
CD and 12 new cases of UC per 100,000 people per year (2, 3). 
Although the etiology of IBD is still elusive, a genetic predisposition, 
environmental factors and an aberrant immune response are all implicated in influencing 
IBD development (4). Studies of IBD in recent years have led to a better understanding of 
its pathogenesis and various aspects of the regulation of the mucosal immune system. IBD 
is manifested by chronic mucosal inflammation and an influx of inflammatory leukocytes. 
Basically, a heightened mucosal immune reaction occurs in response to harmless bacterial 
antigens (5). A variety of immunologic defects, such as an excessive T and B cell 
response, have been identified. 
In healthy individuals, the immune system is able to distinguish between 
commensal bacteria that maintain a symbiotic relationship with their hosts and pathogens 
(6). Receptors expressed by dendritic cells (DC), toll-like receptors (TLR), recognize 
structurally conserved molecular patterns found on microbes. Using TLRs, DCs are able to 
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polarize naive T cell differentiation into regulatory T cells (in response to the commensal 
bacteria) or into effector T cells (in response to pathogens) (4). 
In IBD, several abnormalities of the mucosal immune system have been cited (7). 
First of all, the expression of TLRs goes awry. TLRs that react in the presence of 
pathogens such as TLR4 are up-regulated, while those that maintain homeostasis such as 
TLR3 are down-regulated and suppressed (4). Also, DCs falsely respond to indigenous 
microbial antigens and undergo differentiation leading to disproportionate populations of 
effector T cells and pro-inflammatory responses (8). Pro-inflammatory cytokines such as 
IL-12, IL-18, IL-23, tumor necrosis factor alpha (TNF-a) and IFN yare released and up-
regulate the expression of adhesion molecule ligands on the vascular endothelium 
encouraging leukocyte adhesion and extravasation into the tissue (9-11). T and B 
lymphocytes and macrophages are among the leukocytes that respond to these chemotactic 
signals. Upon reaching the antigen site, macrophages then release chemokines that 
accumulate at endothelial cell surfaces and attract more inflammatory leukocytes, 
continuing the cycle. An interplay of all these immunologic events leads to perpetual 
inflammation in what is known as IBD (5). 
Lymphocyte Homing 
The recruitment process of lymphocytes to the gut involves several sequential steps 
(Fig. 1) (12). The cells are in transit, under high flow conditions in the bloodstream and 
must come to an arrest and proceed through the vasculature to the tissue of interest (13). 
The first step is the primary adhesion which is transient and reversible, accomplished by 
selectins found on lymphocytes binding their ligands on the endothelial cell surface (14). 
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This interaction allows for loose rolling of the lymphocytes along the vessel wall and 
successfully slows their transit. Shortly after the initial contact, the lymphocytes are 
activated by chemokines on the endothelial surface interacting with chemokine receptors 
found on the cells (15, 16). This interaction increases the affinity of integrin receptors for 
their adhesion molecules and promotes their binding. Specifically, the oc4(37 integrin 
receptor on the lymphocyte cell-surface binds the mucosal addressin cell adhesion 
molecule-1 (MAdCAM-1) found on the endothelium. This results in an activation-
dependent arrest and firmly adheres the lymphocytes to the endothelium. Finally, cells 
undergo transmigration, the passage of lymphocytes through intact vessel walls to the 
surrounding tissue (17-19). 
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FIGURE 1. A multi-step model of leukocyte extravasation. This figure was reprinted 
with permission from Dr. Patricia Celie, Department of Molecular Cell Biology and 
Immunology, VU University Medical Center, Amsterdam, the Netherlands. Endothelial 
cells express selectin ligands triggered by inflammation. Selectins are expressed on 
leukocytes, such as L-selectin (not shown), and transiently interact with their ligands 
resulting in a rolling motion over the endothelium. This effectively slows the cells down 
which are in transit in the bloodstream. Then, chemokines generated at the endothelial 
surface, such as CCL25 (not shown), bind with chemokine receptors found on the 
leukocytes, such as CCR9 (not shown), resulting in leukocyte activation. Shortly 
afterwards, the leukocyte integrins, such as a4p7 (not shown), are activated by binding to 
their ligands, such as MAdCAM-l(not shown), on the endothelium. This results in firm 
adhesion of the cell to the endothelial surface. Transmigration of the cell across the 
endothelial barrier follows. 
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Integrins and a4/37 
The integrins, a family of cell adhesion receptors, are comprised of two non-
covalently linked transmembrane glycoprotein subunits, a and p, that form heterodimers 
(20). Intergin receptors mediate interactions of the cells with endothelial tissue via 
ligands called intercellular adhesion molecules (ICAMs) (21). Structure and function 
analysis of the integrin (37 subunit has identified a small region (residues 46-386) that 
accounts for a4(37 binding specificity to its ligand, MAdCAM-1 (21). The oc4(37 integrin is 
expressed on lymphocytes that are destined to migrate to mucosal surfaces, namely CD4+, 
CD8+ T cells, IgA+ plasma cells and plasmablasts (13, 22, 23). 
Strategies for IBD Treatment 
Conventionally, immunosuppressive agents that non-specifically control 
inflammation have been used to treat IBD (24, 25). Recently, therapies that involve 
generating mAbs against molecules specifically involved in the inflammatory cascade have 
been introduced (1). Infliximab, an anti-TNF-a mAb is currently used as therapy for CD 
(26). Other anti-cytokine mAbs that inhibit IFN-y and IL-12 are still being investigated. 
Antibodies that inhibit molecules involved in the migration of leukocytes to the gut have 
also been developed. In animal models, mAbs against the (37 integrin subunit (FEB504) 
and MAdCAM-1 (MECA-367) were able to reduce inflammation in the mouse colon (27). 
For humans, Natalizumab is a humanized anti-a4 integrin mAb that is able to prevent 
oc4(37/MAdCAM-1 interactions. There is one humanized mAb, MLN-02 (also known as 
ACT-1), that specifically recognizes human a4(37 (28). This mAb, however, is not 
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commercially available for research purposes. In this project, we attempt to produce a 
mouse mAb against the human a4(37 integrin to fulfill this need. 
Research Goals 
We adopted a novel immunization strategy to elicit a potent immune response 
against the (37 subunit of the a4(37 heterodimer. It involved immunizing (37 K/O mice with 
WT mouse splenocytes with naturally-occurring (37. The murine (37 subunit was chosen as 
the antigen because residues 46-386 of the murine and human (37 subunit (which account 
for a4(37 specificity for MAdCAM-1) are 92% homologous (21). This homology makes 
the murine {37 suitable for eliciting an immune response that can be boosted with human 
(37. The antibody produced would have a desired specificity to shared epitopes of mouse 
and human (37, in conformation with a4. Such an antibody could be used to test the 
hypothesis that IBD is associated with elevated blood levels of gut-homing lymphocytes, in 
particular plasmablasts. It would enable the tracking of these gut-specific plasmablasts in 
patient blood samples. Along with being linked to the disease state, plasmablast blood 
levels detected by such an antibody and other plasmablast markers could be used to 
monitor patient response to IBD therapy. 
9 
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Abstract 
This study describes the production of a murine monoclonal antibody (mAb3) 
against the human alpha 4 beta 7 (a4(37) gut-homing integrin receptor found on both T and 
B lymphocytes. The recruitment of lymphocytes via the a4(37 receptor to the gut has been 
associated with chronic inflammatory bowel disease (IBD). There is currently only one 
anti-oc4(37 mAb in existence, but it is not commercially available. Studies involving this 
receptor are in need of such an antibody (Ab). A novel immunization strategy was 
employed in generating the desired polyclonal antibodies (pAb) in C57BL/6 mice. 
(37 knock-out (K/O) mice were immunized with (37 wild-type (WT) mouse splenocytes 
with naturally occurring cell-surface (37. As a final boost, mice were injected with human 
peripheral blood mononuclear cells (PBMC), with a rationale of boosting epitopes shared 
between murine and human (37. Immune sera and supernatants of several clones generated 
by hybridoma technology were tested using enzyme-linked immunosorbent assays 
(ELISA) and flow cytometry. In flow cytometric screening assays, the staining pattern of 
the Abs on PBMC expressing human (37 versus a mouse T cell line over-expressing 
a4(37 molecules (TK1) was evaluated. Despite binding to both TK1 cells and PBMCs, the 
mAb produced is unlikely to be anti-a4(37 because it generated a different staining pattern 
than the positive control, ACT-1, on T cell subsets that migrate to the gut. 
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Introduction 
Inflammatory Bowel Disease 
IBD is comprised of Crohn's disease (CD) and ulcerative colitis (UC), two chronic 
intestinal inflammatory conditions that currently affect about 1.4 million people in the 
United States (1). Although the etiology of IBD is still elusive, IBD is manifested by 
chronic mucosal inflammation that results from an aberrant immune response and an influx 
of inflammatory lymphocytes to the gut. This heightened mucosal immune reaction occurs 
in response to harmless bacterial antigens (2). 
In healthy individuals, the immune system is able to distinguish between 
commensal bacteria that maintain a symbiotic relationship with their hosts and pathogens 
(3). In IBD however, DCs falsely respond to indigenous microbial antigens and mature, 
inducing effector T cell and pro-inflammatory responses (4). Pro-inflammatory cytokines 
such as IL-12, EL-18, IL-23, tumor necrosis factor alpha (TNF-a) and IFN y are released 
and up-regulate the expression of adhesion molecule ligands on the vascular endothelium 
encouraging leukocyte adhesion and extravasation into the tissue (5-7). T and B 
lymphocytes and macrophages are among the leukocytes that respond to these chemotactic 
signals. Upon reaching the antigen site, macrophages then release chemokines that 
accumulate at endothelial cell surfaces and attract more inflammatory leukocytes, 
continuing the cycle. An interplay of all these immunologic events leads to perpetual 
inflammation in what is known as IBD (2). 
The recruitment process of lymphocytes to the gut involves several sequential steps. 
The cells are in transit, under high flow conditions in the bloodstream and must come to an 
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arrest and proceed through the vasculature to the tissue of interest (8, 9). Primary adhesion 
which is transient and reversible is accomplished by selectins such as L-selectin found on 
lymphocytes binding their ligands on the endothelial cell surface (10). This interaction 
allows for loose rolling of the lymphocytes along the vessel wall and successfully slows 
their transit. Lymphocytes are then activated by an interaction between chemokines 
generated on the endothelial surface such as CCL25 and chemokine receptors such as 
CCR9 found on the cells (11, 12). This interaction increases the affinity of integrin 
receptors for their adhesion molecules and promotes their binding. Specifically, the 
a4p7 integrin on the lymphocyte cell-surface binds the mucosal addressin cell adhesion 
molecule-1 (MAdCAM-1) found on the endothelium. This results in an activation-
dependent arrest and firmly adheres the lymphocytes to the endothelium. Finally, cells 
undergo transmigration, the passage of lymphocytes through intact vessel walls to the 
surrounding tissue (13-15). 
Structure and function analysis of the integrin [37 subunit of the oc4(37 heterodimer 
identified a small region (residues 46-386) that accounts for oc4p7 binding specificity to its 
ligand, MAdCAM-1 (16). The oc4|37 integrin is expressed on lymphocytes that are 
destined to migrate to mucosal surfaces, namely CD4+, CD8+ T cells, IgA+ plasma cells 
and plasmablasts (9, 17, 18). 
In order to study oc4p7 in association with IBD, an attempt was made to generate a 
mAb against the integrin. A novel immunization strategy was adopted for eliciting a 
potent immune response against the (37 subunit of the a4p7 heterodimer. It involved 
immunizing p7 K/O mice with WT mouse splenocytes with naturally-occurring P7. The 
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murine (37 subunit was chosen as the antigen because residues 46-386 of the murine and 
human (37 subunit (which account for a4(37 specificity for MAdCAM-1) are 92% 
homologous (16). This homology makes the murine (37 suitable for eliciting an immune 
response that can be boosted with human (37. The antibody produced would preferentially 
be against shared epitopes of mouse and human (37, in conformation with a4. 
The purpose of such an antibody was to test the hypothesis that IBD is associated 
with elevated blood levels of gut-homing lymphocytes, in particular plasmablasts. It would 
enable the tracking of these gut-specific plasmablasts in patient blood samples. Along with 
being linked to the disease state, plasmablast blood levels detected by such an antibody and 
other plasmablast markers could be used to monitor patient response to IBD therapy. 
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Materials and Methods 
All studies using animal and human subjects have been reviewed and approved by the 
Institutional Animal Care and Use Committee (IACUC) (Protocol #904) and Human 
Subjects-Institutional Review Board (IRB) (Protocol #F0902030) at San Jose State 
University, San Jose, CA. 
Cells and media 
TK1 is a CD8+ T lymphoma cell line over-expressing a4[37 that originated from a 
spontaneous thymic lymphoma in an AKR/Cum mouse [American Type Culture 
Collection (ATCC) CRL-2396] (a gift of Eugene Butcher's, Stanford University). 
Cryopreserved PBMC were also a gift from Dr. Butcher's lab. They were isolated by a 
Ficoll gradient. Sp2/0 myeloma cells were obtained from San Jose State University. All 
cells were stored in liquid nitrogen until needed, then maintained in culture in 
supplemented RPMI 1640 [2 mM L-glutamine (Lonza), 10% fetal calf serum (FCS) 
(Invitrogen), penicillin (10,000 U/ml)/streptomycin (10,000 |ig/ml)/ amphotericin B (25 
jig/ml) (ThermoScientific), 1 mM sodium pyruvate (ThermoScientific) and 1 mM non-
essential amino acids (NEAA) (Lonza)]. Fresh splenocytes for screening assays and 
immunizations were aseptically removed from female C57BL/6 [37 WT and/or 
(37 K/O mice via splenectomies. Cells were prepared by pressing spleens through a 40 
|i.m nylon mesh strainer (BD Biosciences) while washing with supplemented RPMI 1640. 
Red blood cells in the mixture were lysed with 3 ml of red blood cell lysis buffer (8.3 g/L 
ammonium chloride in 0.01M Tris-HCl buffer, pH 7.5) (Sigma) for 3 min. The 
remaining cells were then washed twice with phosphate buffered saline (PBS) and 
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counted. Feeder layer cells (peritoneal macrophages) were obtained by injecting 10 ml of 
supplemented RPMI 1640 into the peritoneal cavity of a BALB/c mouse with a 22 gauge 
needle and 10 ml syringe, massaging the abdomen and then withdrawing the fluid. 
Immunizations 
Three 6 wk old female C57BL/6 [37 K/O mice (identified as Mouse L, Mouse LR 
and Mouse R) were first immunized subcutaneously (s.c.) with an emulsion of 200 (il of 
complete Freund's adjuvant (CFA) (Sigma) and 100 X 106 (37 WT mouse splenocytes. 
Subsequently, mice were immunized s.c. every 2 wks for approximately 8 wks with an 
emulsion of 200 |J.l of incomplete Freund's adjuvant (IFA) (Sigma) and an average of 70 
X 106 cells per mouse. Approximately 2 wks after the last immunization with (37 WT 
splenocytes, mice were bled and sera were tested by ELISA and flow cytometry assays to 
assess pAb titers. Mice received their last immunization intravenously or 
intraperitoneally with 60 X 106 PBMC (thawed and washed once with PBS) in 200 |ll 
PBS, 3-4 days before fusion. A flow-chart summary of the immunization strategy is 
shown in Fig. 2. 
07 K/O 
cells lack 
07. 
Human 0' 
07 wild-type 
C56BL/6 mouse 
Harvest WT mouse 
splenocytes with cell-
surface (37. 
Inject into CS7BL/6 
07 K/O mice. Mice 
produce pAbs against 
WT mouse 07. 
PBMC with human cell-
surface (37, as booster 
immunization 
Inject into mice 3-4 days 
before fusion. 
Mice produce Abs against 
shared mouse and human 
epitopes of (37. 
/ 
ELISA and FACS analysis 
performed on immune sera to 
confirm the presence of pAb 
against 07. 
Harvest spleens from 
immunized 07 K/O 
mice. 
3 
r -k H 
Fuse cells using PEG. 
Select for hybridomas on HAT media, then screen for anti-
07 antibody production by ELISA and flow cytometry. 
FIGURE 2. Flow-chart summary of the 
immunization strategy. 
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Ab titration using ELISA and flow cytometry 
ELISA: An indirect cell-based ELISA was performed on U-bottom 96-well plates 
(Costar). One to five hundred thousand TK1 cells were seeded per well and blocked at 
room temperature (RT) for 40 min with 150 (il/well blocking buffer (2% FCS, 0.05% 
Tween-20 in PBS). Plates were then centrifuged (300 X g for 5 min), decanted and the 
cells resuspended in 100 |il/well blocking buffer supplemented with 5% goat serum, 
followed by incubation at RT for another 20 min. Plates were then centrifuged, decanted 
and cells were resuspended in 100 |ll/well primary Ab [negative control (anti-Listeria 
monocytogenes pAb), preimmune and immune sera] in blocking buffer. Two-fold serial 
dilutions of each of the primary Abs were made starting with 1/50, followed by 
incubation at 4°C for 1 h. Cell pellets were disrupted by gently shaking plates every 15 
min on a plate shaker (ThermoScientific) for 30 s. After the incubation, cells were 
washed 3 times with 150 [ll/well blocking buffer. One hundred microliters per well of 
alkaline phosphatase-conjugated secondary Ab (goat anti-mouse IgG, whole molecule) 
(Sigma) (1/1000) diluted in blocking buffer was added and cells were incubated for at 
4°C for 1 h. Cells were washed 2 times with 150 (ll/well of blocking buffer and a third 
time with PBS. Plates were decanted and developed with 175 }il/well of alkaline-
phosphatase substrate (1.0 mg/ml p-Nitrophenyl phosphate and 0.2 M Tris buffer) 
(Sigma) dissolved according to the manufacturer's instructions. Thirty to forty-five min 
later when color had developed, absorbance was determined at 405 nm. 
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Flow cytometry analysis: One million TK1 cells/tube were kept on ice and 
blocked with a 1/50 dilution of goat serum in staining buffer (SB) [1% FCS, 0.1% 
sodium azide (Sigma) in PBS] and incubated for 10 min at 4°C. Cells were centrifuged 
(300 X g, 5 min), resuspended with a mixture of goat serum (1/50) and two-fold serial 
dilutions of primary Abs [negative control (anti-Listeria monocytogenes pAb), positive 
control (ACT-1, mouse anti-human a4p7; FIB504, rat anti-mouse (37), preimmune and 
immune sera] and incubated at 4°C for 30 min. Hybridoma supernatants of the positive 
control Abs were a gift from Dr. Butcher's lab, Stanford University. Cells were then 
washed 3 times with SB and resuspended with secondary-labeled Ab, goat anti-mouse 
IgG or goat anti-rat IgG conjugated to phycoerythrin (PE) (Jackson ImmunoResearch) 
and incubated in the dark at 4°C for 30 min. Tubes were then washed 3 times with SB. 
Cells were fixed in 500 (ll/tube of 1% formaldehyde (formalin diluted in PBS) (Sigma) 
and analyzed by flow cytometry (FACSCalibur; BD Biosciences). Ten thousand events 
were acquired in all flow cytometry experiments. Quadrants on dot plots in all flow 
cytometry experiments were set according to the secondary-labeled Ab control. The FL2 
fluorescence detector in the cytometer is able to detect PE which emits a fluorescence 
signal near 585 nm. 
Polyclonal Ab sera assessment for (57 specificity 
Immune sera were assessed by FACS analysis for p7 specificity using a mixture 
of TK1 cells and PBMC, 5 X 105each per tube. Frozen PBMC were thawed, washed 
once with RPMI 1640 to remove DMSO and counted. Staining of PBMC was performed 
as described above for TK1 cells except 1/200 dilutions of preimmune and immune sera 
2 0 
were used as primary Abs. Sera were also tested by flow cytometry on [37 WT and 
(37 K/O splenocytes. Splenocytes were prepared as described above. Two identical 
experiments were run in parallel with the two types of splenocytes. The assay was also 
identical to the one described above for TK1 cells except for some additional steps. A 
1/200 dilution of each mouse serum was used. After washing to remove unbound 
secondary Ab, cells were blocked with a mixture of rat and mouse sera (eBioscience and 
Harlan Bioproducts, respectively) diluted 1/50 and incubated at 4°C in the dark for 10 
min. Cells were washed three times and a mixture of rat serum (1/50), mouse serum 
(1/50) and a 1/200 dilution of rat anti-mouse CD45R/B220 Ab conjugated to FITC (BD 
Pharmingen) was added. Anti-B220 Ab was used to exclude B cells. After a 20 min 
incubation at 4°C in the dark, cells were washed as before, resuspended in 500 jxl/tube of 
1% formaldehyde and analyzed on the FACSCalibur. FITC is detected by the FL1 
fluorescence detector in the cytometer which detects fluorescence signals near 530 nm. 
Fusion 
Three separate fusions were performed using splenocytes from the 3 immunized 
mice (L, LR and R). Three to four days after the final booster, the spleen was removed 
and processed as described above. Healthy Sp2/0 myeloma cells in log phase of growth 
were mixed with splenocytes at a ratio of 1:3. After centrifugation, 2 ml of 50% 
polyethylene glycol (PEG) (Sigma) in plain RPMI-1640 (lacks FCS, sodium pyruvate 
and NEAA) was slowly added to the cell mixture pellet over 1 minute, followed by 2 ml 
of plain RPMI-1640 (over 5 min) and 20 ml of plain RPMI-1640 slowly but not drop-
wise. Cells were centrifuged and resuspended in RPMI-1640 supplemented with 20% 
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FCS and 10% hybridoma cloning factor (CF) (BioVeris Corp) to obtain a concentration 
of 1.3 X 106 cells/ml. Five different concentrations of fused cells (1 X 105, 5 X 104, 2.5 
X 104, 1 X 104 and 5 X 103 cells/well) resuspended in supplemented RPMI (150 fil/well 
final volume) were co-cultured in 96-well flat-bottom plates (Corning Costar 3596) with 
4 X 1 0 cells/well of peritoneal macrophages (as feeder cells). The day after the fusion, 
50 fil/well of 4X HAT medium [hypoxanthine, aminopterin and thymidine (HAT) 
supplement (MP BioMedicals) mixed with RPMI-1640 with 2 mM L-glutamine, 20% 
FCS, penicillin (10,000 U/ml)/ streptomycin (10,000 (Xg/ml)/ amphotericin B (25 (ig/ml), 
1 mM sodium pyruvate, 1 mM NEAA and 50 |iM P-mercaptoethanol] was added to the 
cells to generate IX HAT. 
Hybridoma screening 
Hybridomas were microscopically screened 10-12 days post-fusion. Supernatants 
from single clones occupying at least one third of the bottom of the well were tested by 
ELISA and flow cytometry as described above, using TK1 cells for the ELISA and a 
mixture of TK1 cells and PBMC for the flow cytometric assays. Positive clones (those 
that had atleast 1.6 times higher absorbance values than the preimmune serum for the 
ELISA and considerably brighter staining in flow cytometry) were subcloned by the 
limiting dilution method. 
Limiting dilution 
Twenty-five microliters of resuspended hybridoma cells in supplemented HAT 
media were removed from the positive clone wells and added to a well on a new 96-well 
plate containing 100 (ll of IX HT media (Mediatech) (prepared the same as the HAT 
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media except aminopterin was excluded). Sequential dilutions (1/5) were performed for 
a few additional wells containing 100 |xl of HT media. The contents of a well with an 
average of 25 cells (counted microscopically) were transferred to 40 ml of HT media 
(with 5% CF), mixed and plated onto three 96-well flat-bottom plates (100 (il/well in two 
plates and 200 (il/well in the third plate). 
Flow cytometry analysis of subclones for [37 Specificity 
Subclones from the original positive hybridomas were analyzed for [37 specificity 
with flow cytometry using screening assays as described above. They were tested on a 
mixture of PBMC and TK1 cells and on [37 WT and (37 K/O splenocytes. Positive clones 
were cryopreserved at -80°C for 2 days and then transferred to liquid nitrogen. One to 
two million cells per vial were frozen in 1 ml of freezing media (50% RPMI-1640, 40% 
FCS, 10% DMSO). 
Competition assays 
Positive clones were analyzed in competition assays to see if the Abs they 
produced could block positive control Abs from binding TK1 cells or PBMC. One 
million TK1 cells/tube were first exposed for 30 min to primary Abs, washed and then 
cells were incubated with 50 |ll of FEB504 for 30 min. The cells were washed again 3 
times and resuspended in 100 |il of a 1/100 dilution of goat anti-rat secondary Ab 
conjugated to PE and incubated at 4°C for 30 min. Cells were then fixed with 1% 
formaldehyde and analyzed by flow cytometry. For experiments using PBMC, 1 X 106 
PBMC/tube were blocked with 0.5 (il of goat serum for 10 min. After centrifugation 
(300 X g, 5 min), 50 Jul of primary Abs [FEB504 positive control Ab (supernatant) or 
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preimmune or immune sera (diluted 1/200 in SB) or hybridoma supernatants] were added 
to the cells and incubated at 4°C for 30 min. Cells were then washed and stained with 5 
JLXI of ACT-1 conjugated to allophycocyanin (APC) (a gift of Eugene Butcher's, Stanford 
University) together with 10 jil of mouse blocking serum. They were allowed to incubate 
for 20 min at 4°C in the dark and then washed. Finally, the cells were resuspended in 500 
fil/tube of 1% formaldehyde and acquired by flow cytometry. The FL4 fluorescence 
detector in the cytometer is able to detect APC which emits a fluorescence signal near 
675 nm. 
Multi-color assay 
A multi-color FACS analysis was performed on human PBMC. Hybridoma 
subclone supernatants and the polyclonal Ab serum were used to stain PBMC and their 
staining pattern was compared with the staining pattern generated by the human anti-
a4(37 antibody (ACT-1). One million PBMC were blocked with 0.5 |il goat serum for 10 
min. Fifty microliters of primary Ab was added to tubes with cells and incubated at 4° C 
for 30 min. Cells were washed with 3 ml of SB then resuspended with goat anti-mouse 
secondary Ab conjugated to PE. They were incubated for 30 min (in the dark) at 4° C 
then washed again with 3 ml of SB. A master mix composed of 5 |il/tube anti-CD45RA 
FITC, 10 jil/tube biotinylated anti-cutaneous lymphocyte antigen (CLA), 1 |il/tube anti-
CD4 APC and 5 (il/tube anti-CD62L Cy7 APC was made and added to the cells to isolate 
the desired subset of cells. After a 20 min incubation at 4° C (in the dark), cells were 
washed again with 3 ml of SB. Finally, 1.5 fll/tube streptavidin Cy7 PE were added to 
the tubes that contained biotinylated primary Abs and incubated for another 20 min. 
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After a final 3 ml wash, cells were resuspended with 500 |il/tube SB and analyzed on a 
BD FACSAria flow cytometer (at the VA hospital, Palo Alto/Stanford University flow 
cytometry facility). 
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Results 
EVALUATION OF POLYCLONAL AB SERA 
Assessment ofpAb titers by ELISA and flow cytometry using /37-rich TK1 cells 
(37 K/O mice were immunized with (37 WT mouse splenocytes. Immune sera 
from the mice were tested during the immunization process for pAb titer on TK1 cells 
using two methods: ELISA and flow cytometry (Fig. 3). Absorbance values for the 
immune serum dilutions (red bars) were higher than the preimmune serum dilutions 
(green bars) (Fig. 3A), indicating an immune response against the (37 found on WT 
splenocytes. In flow cytometry experiments, three dilutions of polyclonal serum, 1/50 
and 1/100 (orange peak) and 1/200 (blue peak) all bound (37 found on TK1 cells, as 
reflected by the shift in the cells' fluorescence intensity. In comparison, the preimmune 
serum (brown peak), secondary Ab control (purple peak) and negative control (irrelavant 
pAb) (green peak) (Fig. 3B) did not bind TK1 cells. 
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FIGURE 3. pAb titer assessment using P7-rich TK1 cells. A. ELISA of 
pre- and post-immune sera from mice immunized with (37 WT splenocytes. 
Plates were coated with TK1 cells. B. Flow cytometry analysis of pAb 
sera from mice immunized with 07 WT splenocytes. pAb binding was 
tested on TK1 cells. PE is conjugated to goat anti-mouse secondary Abs 
(FL2-H). Results are representative of similar results obtained with sera 
from all three mice. 
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Specificity ofpAb sera for (37 WT splenocytes versus [37 K/0 splenocytes 
The specificity of the immune sera was further examined by testing on [37 WT 
mouse splenocytes (left column) versus [37 K/O mouse splenocytes (right column) (Fig. 
4C). Sera that are specific for [37 should not bind [37 K/O splenocytes lacking the 
[37 molecule. B cells were excluded from the analysis using anti-B220 Abs conjugated to 
FITC, since cell-surface Abs (IgM and IgD) and Fc receptors found on B cells are known 
to be responsible for non-specific binding. The preimmune serum sample bound only ~6 
% of (37 WT cells. However, a significant percentage of [37 WT cells stained with the 
pAb sera shifted to higher fluorescence values (36.5% for Mouse R, 34.9% for Mouse L 
and 56.6% for Mouse LR), representing the sera's ability to recognize and bind [37. On 
the other hand, there was a significant reduction in [37 K/O cell binding compared to the 
[37 WT cell binding by all three pAb sera. The small percentage of [37 K/O cells that 
were stained (13.0% for Mouse R, 10.3% for Mouse L and 15.0% for Mouse LR) is 
suspected to be non-specific binding or the presence of pAb to non-[37 molecules. Non-
specific binding of the sera can be subtracted resulting in 23.5% of P7 WT cells bound by 
Mouse R serum, 24.6% of [37 WT cells bound by Mouse L serum and 41.6% of p7 WT 
cells bound by Mouse LR serum. As expected, the positive control did not bind 
P7 K/O cells. This assay suggests that the differential binding of the immune pAb to WT 
splenocytes but not to K/O splenocytes reflects the pAb sera binding to P7 molecules. 
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PE is conjugated to goat anti-mouse secondary Abs (FL2-H). 
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Determination of immune sera specificity for mouse and human (37 
To verify that there was an immune response against human (37 as well as mouse 
(37 following the booster with PBMC, flow cytometric assays using a mixture of PBMC 
and TK1 cells were performed (Fig. 5). TK1 cells can be distinguished from PBMC on 
forward scatter based on size since PBMC are significantly smaller than the TK1 cancer 
cells (Fig. 5A). The preimmune serum, secondary Ab control and negative control 
(Listeria monocytogenes pAb) only nonspecifically bound both types of cells, with an 
average of 6% of TK1 cells and 7% of PBMC being bound for the three mice. The pAb 
sera from all three mice bound [37 on the human cells as well as the TK1 cells. The sera 
from Mouse LR, R and L bound 37.6%, 40.6% and 77.4% of the human cells and 93.4%, 
91.6% and 96.7% of TK1 cells, respectively (Fig. 5B). Two positive controls were used 
in this experiment, FEB504 which is a rat anti-(37 mAb that binds both mouse and human 
cells and ACT-1, a mouse anti-a4(37 mAb that exclusively binds human cells. Results 
indicate that both positive controls behaved as expected and that polyclonal sera Abs 
were able to recognize and bind human [37 as well as mouse (37. Flow cytometry was 
preferred over ELISA for future screening experiments because two cell types (such as 
TK1 cells and PBMC) can be mixed and distinguished in flow cytometry simultaneously 
generating information about the sera or supernatants' specificity for both mouse and 
human (37. 
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HYBRIDOMA YIELD FOLLOWING FUSION 
Three separate fusions were performed sequentially based on the highest pAb titer 
of the mouse sera, assessed by several of the experiments described previously. All three 
fusions were successful in producing hybridomas. Approximately 795 hybridomas were 
obtained from three fusions. Mouse L generated 218 clones while Mouse LR and Mouse 
R produced 121 and 456 clones, respectively (Table 1). 
Table 1. Summary of hybridoma yield following fusion 
M o u s e T o t a l 
H y b r i d o m a s 
S ing le 
C l o n e s 
% S i n g l e 
C l o n e s 
O r i g i n a l 
Pos i t i ve 
H y b r i d o m a s 
S u b c l o n e d 
L 218 115 53% 14 13 
LR 121 97 80% 22 11 
R 456 302 66% 77 16 
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SPECIFICITY OF HYBRIDOMA SUPERNATANTS FOR MOUSE AND HUMAN (37 
Hybridomas were initially screened using ELISA (data not shown) and positive 
supernatants were used to stain a mixture of PBMC and TK1 cells in flow cytometric 
assays to determine specificity for (37. A majority of the hybridomas were negative for 
anti-(37 Ab. However, Mouse L produced 14 hybridomas that responded to the 
[37 antigen. Mouse LR and Mouse R produced 22 and 77 positive hybridomas, 
respectively (Table 1). A few of the positive hybridomas exhibiting different staining 
patterns, G5-H5, F9-D3, D6-E12, B7-E8 and F4-A9 are depicted in Fig. 6 along with an 
example of a negative hybridoma. Several of the positive hybridomas were subcloned by 
limiting dilution. 
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FIGURE 6. Flow cytometric screening of original hybridoma 
supernatants on mixed TK1 and PBMC populations. Dot plots are gated 
on TK1 cells (red) and PBMC (green) populations, R2 or Rl , respectively 
(not shown). PE is conjugated to goat anti-mouse secondary Abs (FL2-H). 
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Subclones were retested by flow cytometry and many showed staining patterns 
similar to those generated by the original hybridomas. Those that remained positive 
(subclones of hybridoma G5-H5, F9-D3, D6-E12, B7-E8 and F4-A9) are examined in 
Fig. 7. Judging from their staining patterns, G5-H5 is an example of a clone that binds 
TK1 cells only and not PBMC while clone F9-D3 shows the opposite by binding only 
PBMC. D6-E12 is a clone that binds both types of cells moderately well. Furthermore, 
clones B7-E8 and F4-A9 seemed to produce Abs that recognized (37 well on both types of 
cells. Subclone F4-A9 showed higher specificity for the TK1 cells than the original F4-
A9 hybridoma. An example of a negative subclone from hybridoma F4-A9 that did not 
produce anti-(37 Ab is also shown. 
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To further investigate the specificity of these clones for (37, supernatants were 
also evaluated on (37 WT splenocytes versus (37 K/O mouse splenocytes like the sera 
(Table 2). None of the supernatants bound well to the (37 WT cells (represented by mean 
fluorescence values in the FL2 channel). The pAb serum also did not respond to the 
(37 WT splenocytes as well as it did in previous experiments. Only the positive control 
FIB504 bound the (37 WT cells. Furthermore, there was no significant reduction in the 
mean fluorescence when the supernatants were applied to (37 K/O cells. The positive 
control solely displayed a reduction in the mean fluorescence values when bound to 
(37 K/O cells versus being bound to (37 WT cells. 
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Table 2. Hybridoma subclone supernatant screening on P7 WT versus 
[37 K/O mouse splenocytes3 
Primary 
Antibody 
p7 WT Splenocytes 
FL2 (PE) 
Arithmetic Mean 
Fluorescence 
(Arbitrary Units) 
p7 K/O 
Splenocytes 
FL2 (PE) 
Arithmetic Mean 
Fluorescence 
(Arbitrary Units) 
Listeria pAb 
(Negative Control) 
8.89 16.77 
FIB504 Positive 
Control 
48.45 9.41 
Preimmune Serum 13.29 16.50 
Mouse R pAb 
Serum 
28.43 24.40 
Subclone G5-H5 
supernatant 
9.45 17.04 
Subclone B7-E8 
supernatant 
8.89 17.19 
Subclone D6-E12 
supernatant 
13.41 16.53 
Subclone F4-A9 
supernatant 
33.09 40.23 
Subclone F9-D3 
supernatant 
15.53 15.35 
a
 Binding of anti-|37 Ab found in the subclone supernatants to 
splenocytes is represented by mean fluorescence values (arbitrary 
units) in the FL2 channel. Goat anti-mouse secondary Abs are 
conjugated to PE. B cells were excluded from the flow cytometry 
analysis with anti-B220 Abs conjugated to FITC. 
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COMPETITION ASSAYS TO ASSESS AB FUNCTION 
In order to assess if the Abs produced by these clones were blocking Abs able to 
block the positive controls FIB504 (Table 3) and/or ACT-1 (Table 4) from binding [37, 
competition assays were performed. The positive control samples were not blocked by 
primary Ab. Neither the polyclonal serum nor the supernatants were able to block the 
FEB504 Ab from binding [37 on the TK1 cells, since no reduction in mean fluorescence 
can be detected compared to the positive control (Table 3). In the competition assay 
using ACT-1 Ab, only the FIB504 was able to block the Ab from binding [37 on the 
PBMC. This is evident from the reduction of the mean fluorescence in the FIB504 
sample. The polyclonal serum as well as the supernatants did not block the ACT-1 Ab, 
reflected by the mean fluorescence values remaining consistently high (Table 4). The 
results of both competition assays suggest that none of the clones produce blocking Abs 
Table 3. FIB504 competition assay to assess the subclone 
supernatant Abs' ability to block FIB504 from binding (37 on 
TK1 cells3 
Primary Antibody TK1 cells FL2 (PE) Arithmetic 
Mean Fluorescence 
(Arbitrary Units) 
FIB504 Positive 
Control 
756.39 
Listeria pAb 
(Negative Control) 
734.41 
Preimmune Serum 719.87 
Mouse LR pAb Serum 659.34 
Subclone G5-H5 
supernatant 
751.82 
Subclone B7-E8 
supernatant 
735.63 
Subclone D6-E12 
supernatant 
749.28 
Subclone F4-A9 
supernatant 
768.43 
Subclone F9-D3 
supernatant 
750.05 
a
 Mean fluorescence values (arbitrary units) represent goat 
anti-rat secondary Abs (conjugated to PE) binding rat-anti 
mouse (37 (FIB504). 
Table 4. ACT-1 competition assay to assess the subclone 
supernatant Abs' ability to block ACT-1 from binding a4p7 on 
PBMCa 
Primary Antibody PBMC 
FL4 (APC) 
Arithmetic Mean Fluorescence 
(Arbitrary Units) 
ACT-1 Positive 
Control 
35.54 
FIB504 Positive 
Control 
11.21 
Listeria pAb 
(Negative Control) 
34.91 
Preimmune Serum 34.79 
Mouse LR pAb Serum 33.01 
Subclone G5-H5 
supernatant 
33.93 
Subclone B7-E8 
supernatant 
36.62 
Subclone D6-E12 
supernatant 
35.42 
Subclone F4-A9 
supernatant 
32.06 
Subclone F9-D3 
supernatant 
35.57 
a
 Mean fluorescence values (arbitrary units) represent anti-
a4p7 ACT-1 (directly conjugated to APC) binding PBMC. 
4 1 
MULTI-COLOR ASSAY TO ASSESS AB BINDING TO A SUBSET OF T CELLS 
Finally, the supernatants combined with additional multi-color antibodies were 
used to stain PBMC, focusing on CD4+ effector memory T helper cells that migrate to 
the gut. These cells are also CD45RA|0VV CD62Llow and have suppressed levels of CLA. 
The staining patterns of subclone supernatants were compared with the staining pattern 
generated by the ACT-1 positive control (Fig. 8, C and D). The supernatants' ability to 
bind this specific type of T cell subset and generate a pattern similar to that of the 
positive control ACT-1 would indicate the presence of anti-a4|37 antibodies that 
recognize the integrin. Compared to the ACT-1 Ab however, the Abs found in the 
subclone supernatants and the polyclonal Ab serum generated different staining patterns 
on effector memory T cells (Fig. 8, C and D). The ACT-1 showed three distinct 
populations indicating the presence of cell populations that specifically migrate to the 
gut, the skin or neither (Fig.8D). However, both the polyclonal Ab serum and subclone 
supernatants only revealed two distinct populations: one that was CLA negative and 
presumably 07 positive and another which was positive for both CLA and (37, which is 
unlikely because effector memory T cells would migrate to one or the other destination, 
not both. 
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Discussion 
Along with a dysregulated mucosal immune system, IBD involves constant 
recruitment of lymphocytes circulating in the blood to the gut. The a407 integrin 
expressed by lymphocytes mediates their binding to the vascular endothelium via the 
MAdCAM-1 ligand and facilitates their transmigration into the gut tissue (2). In this 
study, an attempt was made to produce an anti-a407 Ab that could potentially be used to 
track and study gut-homing lymphocytes associated with IBD, since the only anti-
a407 Ab in existence is not commercially available for research. 07 K/O mice were 
immunized with naturally-occurring 07 found on WT mouse splenocytes and PBMC. 
The rationale for immunizing with both mouse and human cells was to generate 
polyclonal Abs against shared epitopes of mouse and human 07. After an immune 
response was confirmed against the 07, hybridoma technology was used to generate 
clones secreting anti-07 Abs. Screening assays were optimized to identify and isolate 
these hybridomas. The Ab produced, F4-A9, generated different staining patterns than 
the positive control, ACT-1 when binding to a subset of T cells that migrate to the gut. 
This indicates that the Ab is different from the ACT-1 mAb and unlikely to be anti-a407. 
Our results indicate that the immunization strategy was effective in eliciting an 
immune response but could be improved. The naturally-occurring cell-surface 07 subunit 
on WT mouse splenocytes was immunogenic and induced an immune response in 
07 K/O mice as evident by the 07 antigen-specific polyclonal Abs. The post-immune 
sera reacted with mouse 07 on TK1 cells and WT splenocytes as well as with human 
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07 on PBMC but not with (37 K/O splenocytes. Non-specific binding of the sera to 
07 K/O splenocytes may have been due to Abs generated against other epitopes on WT 
splenocytes, although ideally the only difference between the [37 WT mice and the K/O 
mice should have been the 07 molecule found on WT mouse cells. 
The immune response was good but the number of plasma cells secreting anti-
07 Abs could be enhanced through several avenues such as increasing the frequency and 
number of immunizations or exploring other modes of antigen administration (19). In 
addition, alternative immunogens can be used such as synthetic 07 peptides conjugated to 
carrier proteins or T lymphoma cells over-expressing a407 (TK1). 
The success of the next step in 07 specific mAb production, the fusion, relied on 
the successful union of myeloma cells with highly-specific plasma cells. Many factors 
regarding the two cells types must be accounted for in order to generate the desired 
number of hybridomas. An average of 265 hybridomas per fusion were obtained. 
Although a reasonable number, it could be increased with an improved technique. 
Essentially, the best way to get a better yield of anti-07 Ab producing hybridomas would 
have been to have the optimal number of 07 specific plasma cells, rather than naive B 
cells, available at the time of fusion. Furthermore, the ratio of the two cell types during 
the fusion is also an important factor in generating hybridomas (20). We used a 1:3 ratio 
of Sp2/0 myeloma cells to splenocytes, although the ideal is 1:2. This may have affected 
our fusion, since there were many more splenocytes than their myeloma partners. Yet 
other factors influencing the fusion are the handler's technical experience and conditions 
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during the fusion. Gentle handling combined with the optimum temperature and media 
will ensure the survival of cells through stressful conditions. 
Once the hybridomas were screened for (37 specificity, staining patterns of PBMC 
and TK1 cells were evaluated. Hybridoma supernatants stained the cells differentially. 
In some cases, for example hybridoma G5-H5, two distinct populations, one positive and 
the other negative for (37, were observed. More than one Ab might be present in the 
supernatants from these hybridomas, requiring subcloning. Additionally, since the cells 
may not all be in identical stages of the cell cycle, a dividing population may exhibit 
differential expression of cell-surface antigens. In some other cases, a range was 
observed in PBMC and TK1 cell staining. This can be explained as cells binding the Abs 
with different intensities due to the epitopes for Ab binding not being exposed the same 
on all cells. 
When the supernatants were examined on (37 WT versus (37 K/O splenocytes, 
overall low fluorescence values and no reduction in binding to K/O cells was observed. 
This could be attributed to low Ab concentration, or it could mean the hybridomas lost 
the ability to produce Ab. Moreover, the pAb serum did not function as well as it did in 
previous experiments. Freeze-thaw cycles may have affected the integrity of the 
polyclonal Abs. 
Functional analyses demonstrated that the Abs could not inhibit positive control 
Abs from binding (37. This could mean that these Abs bound different epitopes than the 
positive control Abs and therefore could not block. It could also mean that the Abs were 
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not blocking Abs, or it is possible that the supernatants again had low concentrations of 
Ab or no Ab at all. 
Finally, the Abs were tested for binding to effector memory T cells known to 
migrate to the gut, and staining patterns were compared to those of the well-established 
ACT-1 mAb. Effector memory T cells that migrate to the gut have a407, and those that 
migrate to the skin have CLA. Effector memory T cells stained with ACT-1 showed 
three populations, effector memory T cells that have CLA and migrate to the skin, those 
that do not have CLA but rather a407 and migrate to the gut, and some that have neither. 
In the polyclonal Ab serum and the mAb samples, however, only two populations were 
observed: one that seemed positive for (37 but not CLA and another that seemed positive 
for both. The latter population is unusual because effector memory cells would express 
one type of homing molecule and suppress the other, resulting in migration to the gut or 
skin, not both. This indicates that the Abs in the polyclonal Ab serum as well as the 
mAbs are different from ACT-1 and unlikely to be anti-a4(37. 
In summary, this paper describes a novel immunization strategy to generate an 
a4(37 mAb and the development of screening procedures to isolate specific anti-(37 
secreting hybridomas. Further work will be needed to identify additional 07 specific 
hybridomas and stabilize mAb production in culture. Methods to optimize the immune 
response need to be evaluated. A better immune response, composed of Abs with 
improved 07 specificity, will make improved identification and isolation of hybridomas 
producing highly-reactive Abs with the desired specificity for 07. 
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DISCUSSION 
Along with a dysregulated mucosal immune system, IBD involves constant 
recruitment of lymphocytes circulating in the blood to the gut. The a4(37 integrin 
expressed by lymphocytes mediates their binding to the vascular endothelium via the 
MAdCAM-1 ligand and facilitates their transmigration into the gut tissue (4). In this 
study, we attempted to produce an anti-a4(37 Ab that could potentially be used to track 
and study gut-homing lymphocytes associated with IBD, since the only anti-a4[37 Ab in 
existence is not commercially available for research. p7 K/O mice were immunized with 
naturally-occurring P7 found on WT mouse splenocytes and PBMC. The rationale for 
immunizing with both mouse and human cells was to generate polyclonal Abs against 
shared epitopes of mouse and human p7. After an immune response was confirmed 
against the (37, hybridoma technology was used to generate clones secreting anti-P7 Abs. 
Screening assays were optimized to identify and isolate these hybridomas. The antibody 
produced generated different staining patterns than the positive control, ACT-1 when 
binding to a subset of T cells that migrate to the gut. 
Our results indicate that the immunization strategy was effective in eliciting an 
immune response but could be improved. The naturally-occurring cell-surface P7 subunit 
on WT mouse splenocytes was immunogenic and induced an immune response in 
P7 K/O mice as evident by the P7 antigen-specific polyclonal Abs. The post-immune 
sera reacted with mouse p7 on TK1 cells and WT splenocytes as well as with human 
P7 on PBMC but not with p7 K/O splenocytes. Non-specific binding of the sera to 
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(37 K/O splenocytes may have been due to Abs generated against other epitopes on WT 
splenocytes, although ideally the only difference between the (37 WT mice and the K/O 
mice should have been the (37 molecule found on WT mouse cells. 
The immune response was good but the number of plasma cells secreting anti-
(37 Abs could be enhanced through several avenues. First, the mice can be exposed to 
more of the antigen by increasing the number of splenocytes used for the immunizations 
or increasing the frequency and number of immunizations. Second, other modes of 
antigen administration can be explored, such as injecting footpads associated with lymph 
nodes rather than the s.c. or i.p. methods commonly targeting the spleen. Finally, 
alternative immunogens can be used such as synthetic (37 peptides conjugated to carrier 
proteins. Abs generated by synthetic peptide antigens have the advantage of binding 
denatured proteins. However, unlike whole cell generated Abs they may not bind 
globular proteins and have limited function (29). In contrast, Abs generated to whole 
cells may have a broader range of functional activities. The Abs can be fluorescently-
tagged and used to stain cells expressing the epitope of interest and/or they can be used to 
block receptor/ligand interactions. If immunizations with whole cell antigens are 
continued for this study, immunizations with T lymphoma cells over-expressing 
a4(37 (TK1) can be used as an alternative. However, the cells would need to be treated 
with mitomycin C to repress cell growth prior to the immunizations. 
The success of the next step in (37 specific mAb production, the fusion, relied on 
the successful union of myeloma cells with highly-specific plasma cells. Many factors 
regarding the two cells types must be accounted for in order to generate the desired 
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number of hybridomas. We obtained an average of 265 hybridomas per fusion. 
Although a reasonable number, it could be increased with an improved technique. 
Essentially, the best way to get a better yield of anti-P7 Ab producing hybridomas would 
have been to have the optimal number of [37 specific plasma cells, rather than naive B 
cells, available at the time of fusion. More sources of plasma cells such as lymph nodes 
could have been sought along with the spleen. P7 specific plasma cells could also have 
been enriched by passing the splenocytes through column chromatography, with 
P7 molecules attached to column beads. In addition, P7 specific plasma cells could be 
sorted using fluorescently-tagged P7. Furthermore, the ratio of the two cell types during 
the fusion is also an important factor in generating hybridomas (30). We used a 1:3 ratio 
of Sp2/0 myeloma cells to splenocytes, although the ideal is 1:2. This may have affected 
our fusion, since there were many more splenocytes than their myeloma partners. 
Moreover, it was once believed the histocompatible relatedness of the two types of cells 
being fused plays a role on hybridoma stability (30). Our fusion also involved cells from 
two different strains of mice; C57BL/6 splenocytes were fused with Sp2/0 myeloma cells 
originating from a BALB/c mouse. The average of 265 hybridomas per fusion may have 
been higher if cells from the same strains had been used for the fusion. Yet other factors 
influencing the fusion are the handler's technical experience and conditions during the 
fusion. Gentle handling combined with the optimum temperature and media will ensure 
the survival of cells through stressful conditions. Hybridoma yield could have also been 
influenced by our plating method since we tried to obtain the maximum number of single 
clones by plating different concentrations of the fused cells. Although we were able to 
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get high percentages of single clones, this perhaps compromised our overall yield of 
positive hybridomas. 
Screening assays need to be optimized for the identification and isolation of anti-
(37 Ab-producing hybridoma cell lines. These assays must be able to process hundreds of 
samples simultaneously and identify positive clones within 48 hours (29). They must 
also be proven to be specific and sensitive for the antigen-Ab reaction. The ELISA, 
using TK1 cells, was able to process multiple samples; however, it was not as sensitive as 
the flow cytometry assays. Furthermore, unlike flow cytometry, in the ELISA, PBMC 
could not be mixed with TK1 cells to provide information simultaneously on both anti-
human and anti-mouse (37 Abs. Although flow cytometry has these advantages, a 
disadvantage of flow cytometry is that samples can be prepared only in FACS tubes. 
This limits the number of samples that can be analyzed. Overall, our screening assays 
were reliable and reproducible; however, we need an assay that will combine efficiency 
with sensitivity. 
Once the hybridomas were screened for (37 specificity, staining patterns of PBMC 
and TK1 cells were evaluated. Hybridoma supernatants stained the cells differentially. 
In some cases, for example hybridoma G5-H5, two distinct populations, one positive and 
the other negative for (37, were observed. More than one Ab might be present in the 
supernatants from these hybridomas, requiring subcloning. Additionally, since the cells 
may not all be in identical stages of the cell cycle, a dividing population may exhibit 
differential expression of cell-surface antigens. In some other cases, a range was 
observed in PBMC and TK1 cell staining. This can be explained as cells binding the Abs 
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with different intensities due to the epitopes for Ab binding not being exposed the same 
on all cells. 
When the supernatants were examined on (37 WT versus (37 K/O splenocytes, 
overall low fluorescence values and no reduction in binding to K/O cells was observed. 
This could be attributed to low Ab concentration, or it could mean the hybridomas lost 
the ability to produce Ab. Moreover, the pAb serum did not function as well as it did in 
previous experiments. Freeze-thaw cycles may have affected the integrity of the 
polyclonal Abs. 
Functional analyses demonstrated that the Abs could not inhibit positive control 
Abs from binding (37. This could mean that these Abs bound different epitopes than the 
positive control Abs and therefore could not block. It could also mean that the Abs were 
not blocking Abs, or it is possible that the supernatants again had low concentrations of 
Ab or no Ab at all. The hypothesis that the hybridomas lost the ability to produce Abs 
needs to be further examined. 
Some clones may have lost the ability to produce Ab as a result of being in culture 
for an extended period of time. The stability of the clones in terms of Ab production may 
have been compromised due to high cell density (30). High cell density can lead to 
buildup of toxic waste material and competition for nutrients, and eventually cells may 
begin to self-regulate their growth and enter a lag phase. Some hybridomas may stop 
producing Ab, once they have experienced this event. In addition, studies have shown 
that cell proliferation and Ab production are not necessarily correlated (31). Even though 
some clones looked healthy and grew well, conditions for Ab production might not have 
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been met. Ideal serum concentrations, for example, have been shown to be different for 
cell growth versus Ab production. FCS was reduced to 10% from the original 20% in 
order to wean the cells from serum dependency. This sudden change could have led to a 
drop in Ig secretion. A more gradual change would have been preferred to allow the cells 
to adapt. 
Loss of function of Ab-producing hybridomas can also be attributed to the 
unstable nature of the hybrid cell chromosome. Although it might not be true for our 
allogeneic fusion, it has been shown that in xenogeneic fusions the non-mouse myeloma 
genes compete with the mouse heavy chain immunoglobulin locus on the B cell 
chromosome for expression (30). In fact, the myeloma chromosome may even repress 
the B cell chromosome from translating Abs and go as far as to prevent replication of Ab 
genes. These explanations provide insight into our hybridomas' lack of ability to produce 
Ab. The next time we handle antibody-secreting hybridomas, we would ensure the 
clones are screened while they are in log phase of growth before they enter a lag phase 
and stop producing Ab. 
Finally, the Abs were tested for binding to effector memory T cells known to 
migrate to the gut, and staining patterns were compared to those of the well-established 
ACT-1. Effector memory T cells that migrate to the gut have oc4p7, and those that 
migrate to the skin have CLA. Effector memory T cells stained with ACT-1 showed 
three populations, effector memory T cells that have CLA and migrate to the skin, those 
that do not have CLA but rather a407 and migrate to the gut, and some that have neither. 
In the polyclonal Ab serum and the mAb samples, however, only two populations were 
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observed: one that seemed positive for (37 but not CLA and another that seemed positive 
for both. The latter population is unusual because effector memory cells would express 
one type of homing molecule and suppress the other, resulting in migration to the gut or 
skin, not both. This indicates that the Abs in the polyclonal Ab serum as well as the 
mAbs are different from ACT-1 and unlikely to be anti-a4b7. 
Once an anti-|37 Ab is identified from the hybridomas, it can be characterized and 
its function further analyzed. Like the competition assays where the Abs were tested for 
the ability to block positive controls from binding [37, a chemotaxis assay can prove 
useful in assessing Ab function. This assay can test if the anti-a4[37 Ab is able to inhibit 
gut-specific cells expressing a4[37 from migrating to the a4(37 ligand, MAdCAM-1, thus 
interfering with interaction essential for gut-homing. 
An anti-a4(37 Ab may be used to test the hypothesis that IBD is associated with 
elevated blood levels of gut-homing plasmablasts. Plasmablasts are premature plasma 
cells that express a4[37 if they are destined to migrate to the gut. This Ab would be able 
to track and quantify gut-specific plasmablast levels in patient blood samples and monitor 
how the levels change in response to commonly-used therapies against IBD. This would 
be accomplished by FACS analysis of PBMCs from IBD patients using plasmablast 
markers such as CD 19+, CD38+, CCR10 and CCR9 along with the a4[37 integrin. CD 19 
and CD38 are markers found on plasma cells, while CCR10 and CCR9 are involved in 
cell trafficking and migration to sites of inflammation. Additionally, it is important to 
observe plasmablasts in the blood, because several cases of IBD treated with anti-
TNFa mAb have resulted in rare and fatal plasmablast lymphomas (32). Studying 
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plasmablasts may shed light on more aspects of the commonly used anti-TNFa mAb 
treatment. An anti-a407 Ab would provide the means to look into these clinical and 
research issues. 
In summary, this paper describes a novel immunization strategy to generate an 
a407 mAb and the development of screening procedures to isolate specific anti-07 Ab-
secreting hybridomas. Further work will be needed to identify additional 07 specific 
hybridomas and stabilize mAb production in culture. Methods to optimize the immune 
response need to be evaluated. A better immune response, composed of Abs with 
improved 07 specificity, will make improved identification and isolation of hybridomas 
producing highly-reactive Abs with the desired specificity for 07. 
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San Jose State University 
Institutional Animal Care and Use Committee 
LETTER OF OFFICIAL PROTOCOL REVIEW 
Date: July 24. 2007 
Dear Dr Abramson, 
The animal care and use portion o f your research proposal indicated below was reviewed 
by the Institutional Animal Care and Use Committee ( IACUC). The status of your 
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Principal Investigator/s: Tzvia Abramson 
Co-investigator/s: Asima Khan 
Protocol #: 904 
Title: Bio-233 Lab Unit: Production of Specific I m m u n e Response in Balb/c 
mice for production<jf Monoclonal Antibodies. 
The application w a s approved without modif ication by the IACUC. 
Approval date: August 22, 2007 * Expiration Date: August 21, 2010 
The I A C U C must be informed in writing of any proposed changes to the approved 
protocol outline and approval must be granted in writ ing by the I A C U C before any 
change is instituted. If you wish to continue the approved outl ine beyond the expiration 
date, it is required that you resubmit an animal care and use application for IACUC 
review and approval in June 2010. 
The protocol number (#904) may only be used by the instructor and part icipants included 
on the approved application form. The protocol number will be required to order animals 
for this study (maximum 105 mice). Submitting animal order and delivery requisitions is 
the responsibility of the Principal Investigator and orders are to be placed through the 
University Animal Care of f ice in ample time before the study. If you have any questions, 
feel free to contact me at extension 924-4929. 
v i 
This protocol has been a p p r o v e d as a Health 
Risk Category T w o level p ro jec t (RC-2). 
Larry Young, ftVT, CPIA 
IACUC Coordinator 
Please refer to the a t t ached risk ca tegory 
description page for re levant personnel 
safety information pe r t a in ing to this study. 
Cl UAC Oil' 
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Dr. Tzvia Abramson 
Depar tment of Biological Sciences 
San Jose State University 
One Wash ing ton Square 
San Jose CA. 95l<>2-0100 
/ O 
From: Pamela Stacks. Ph.D. / 
Associate Vice President 
Graduate Studies and Research 
Date February 25. 2009 
The Human Subjects-Inst i tut ional Review Board has registered your study 
entitled: 
"'Production of a murine monoclonal ant ibody against the human 
a lpha4be ta7 gm-homing integrin r e c e p t o r ' 
Th i s registration, which provides exempt status under Exempt ion 
Ca teeory 4 of S.tSU Policy SOS-7. is contingent upon the subjects included 
in vour research project being appropriately protected f r o m risk. 
Specif ica l ly . protect ion of the anonymiry oJ'I he .subjects' identity with 
regard to all data that may be collected about the sub jec t s f rom your 
secondary sources needs to be ensured. 
This registration includes cont inued moni tor ing of your research by the 
Board to assure that the subjects are being adequate ly and proper ly 
protected f rom such risks. If at any t ime a subject becomes injured or 
compla ins of injury, you must notify Dr. Pamela Stacks . Ph.D. 
immediate ly , injury includes but is not limited to bodily ha rm, 
psychological t rauma, and release of potentially damaging personal 
informat ion. This approval for the human sub jec t ' s portion of your project 
i.s in effect for one year, and data collection beyond February 25, 2010 
requires an extension request. 
If vou have any quest ions, please contact me at (40Si 924-2427. 
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